Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/919"

Predicate	Value (sorted: none)
rdf:type	?:Evidence
rdf:type	?:Item
rdfs:label	"evidence_1572"
?:Evidence_type	?:Non_traceable_Drug_Label_Statement
?:Evidence_assump_list_id	"166"
?:Evidence_enzyme_system	""
?:claim_assumed_valid_for_evidence_application_evidence_1572	?:ketoconazole_in_viVo_selective_inhibitor_of_enzyme_cyp3a4
dc:creator	"boycer"
dc:date	"01/11/2010 18:27:15"
?:content	"Both CYP3A4 and CYP2D6 are responsible for iloperidone metabolism. Inhibitors of CYP3A4 (e.g., ketoconazole) or CYP2D6 (e.g., fluoxetine, paroxetine) can inhibit iloperidone elimination and cause increased blood levels. Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18-45, increased the AUC of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively. Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole). Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level."
rdfs:seeAlso	?:33f60b40-3fca-11de-8f56-0002a5d5c51b

The resource appears as object in one triple:

{ iloperidone_substrate_of_cyp3a4, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1572 }

Context graph